Lausanne, Switzerland, July 3, 2023 – AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at ...
- Company to further expand its DECODE™ discovery platform, accelerate multiple oncology clinical programs, and advance discovery programs in oncology, autoimmune disorders, infectious disease, and ...
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...
Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different 'program' that makes them less effective than immune cells ...
The purpose of this undergraduate minor is to leverage Drexel’s unique strengths and leadership in this area to advance the education of the next generation of leaders in immune engineering. Students ...
– NEON-1, clinical trial with ALPN-202 monotherapy, proceeds through dose escalation – – New discovery efforts yield novel preclinical fusion proteins that enable tumor antigen-dependent CD28 ...
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that, following advancement of key startup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results